← Oncology Approval Tracker

FDA DECISION ·

Xeloda

capecitabine · Genentech

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Single-agent treatment of advanced or metastatic breast cancer when anthracycline- or taxane-containing chemotherapy is unsuitable.

LAMPGEN ANALYSIS

Why it matters

This revision clarifies the monotherapy population and accompanies updated dosing options.

What research teams should watch

Record why an anthracycline or taxane is unsuitable and document the selected starting dose and follow-up.

PRIMARY RECORDS

Sources